Triptonodiol, a Diterpenoid Extracted from Tripterygium wilfordii , Inhibits the Migration and Invasion of Non-Small-Cell Lung Cancer

Lung cancer is the most prevalent oncological disease worldwide, with non-small-cell lung cancer accounting for approximately 85% of lung cancer cases. is a traditional Chinese herb that is widely used to treat rheumatism, pain, inflammation, tumors, and other diseases. In this study, we found that...

Full description

Saved in:
Bibliographic Details
Published in:Molecules (Basel, Switzerland) Switzerland), 2023-06, Vol.28 (12), p.4708
Main Authors: Ni, Xiaochen, Jiang, Xiaomin, Yu, Shilong, Wu, Feng, Zhou, Jun, Mao, Defang, Wang, Haibo, Liu, Yanqing, Jin, Feng
Format: Article
Language:English
Subjects:
actin cytoskeleton remodeling
Apoptosis
Autophagy
Cancer therapies
Carcinoma, Non-Small-Cell Lung - pathology
Cell Line, Tumor
Cell Movement
Cells
Cytoskeleton
Cytotoxicity
Diterpenes - pharmacology
Drugs
Epidermal growth factor
Extracellular matrix
invasion and metastasis
Kinases
Lung cancer
Lung Neoplasms - pathology
Medical prognosis
Metastasis
Motility
Neoplastic Processes
non-small-cell lung cancer
Proteins
Tripterygium
Tripterygium wilfordii
Triptonodiol
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lung cancer is the most prevalent oncological disease worldwide, with non-small-cell lung cancer accounting for approximately 85% of lung cancer cases. is a traditional Chinese herb that is widely used to treat rheumatism, pain, inflammation, tumors, and other diseases. In this study, we found that Triptonodiol extracted from inhibited the migration and invasion of non-small-cell lung cancer and inhibited cytoskeletal remodeling, which has not been previously reported. Triptonodiol significantly inhibited the motility activity of NSCLC at low toxic concentrations and suppressed the migration and invasion of NSCLC. These results can be confirmed by wound healing, cell trajectory tracking, and Transwell assays. We found that cytoskeletal remodeling was inhibited in Triptonodiol-treated NSCLC, as evidenced by the reduced aggregation of actin and altered pseudopod morphology. Additionally, this study found that Triptonodiol induced an increase in complete autophagic flux in NSCLC. This study suggests that Triptonodiol reduces the aggressive phenotype of NSCLC by inhibiting cytoskeletal remodeling and is a promising anti-tumor compound.
ISSN:1420-3049
1420-3049
DOI:10.3390/molecules28124708